Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of “Moderate Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $14.20.

Several research firms recently issued reports on CMPX. Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Tuesday, March 24th. Craig Hallum began coverage on Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently added to or reduced their stakes in CMPX. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at about $30,000. Flagship Harbor Advisors LLC bought a new position in Compass Therapeutics in the fourth quarter valued at about $32,000. Strs Ohio bought a new position in Compass Therapeutics in the first quarter valued at about $34,000. Finally, Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the third quarter valued at about $35,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $6.00 on Friday. Compass Therapeutics has a twelve month low of $1.66 and a twelve month high of $6.88. The firm has a market cap of $1.08 billion, a PE ratio of -13.95 and a beta of 1.49. The business has a fifty day moving average of $5.68 and a 200-day moving average of $5.23.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. On average, analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.